Cite
HARVARD Citation
Burns, J. et al. (2021). Infliximab versus second intravenous immunoglobulin for treatment of resistant Kawasaki disease in the USA (KIDCARE): a randomised, multicentre comparative effectiveness trial. Lancet. pp. 852-861. [Online].